Melipramin

Imipramine Hydrochloride, the active ingredient in Melipramin, is a tricyclic antidepressant presented as an oral tablet for systemic use. It is prescribed for the treatment of major depressive disorder, panic disorder, and nocturnal enuresis in adult patients. The medication works by modulating neurotransmitter levels in the brain, thereby improving mood and reducing anxiety symptoms.

GNH USA supplies Melipramin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures consistent quality and regulatory compliance across diverse markets.

Imipramine Hydrochloride, a tricyclic antidepressant, is used to treat several psychiatric and urological conditions.

- Major depressive disorder: alleviates depressive symptoms and improves overall mood. - Panic disorder: reduces the frequency and severity of panic attacks. - Nocturnal enuresis: decreases nighttime urinary episodes in children and adolescents.

Imipramine Hydrochloride may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dry mouth: reduced salivary secretion causing discomfort. - Constipation: slowed gastrointestinal motility. - Drowsiness: increased sedation, especially at treatment initiation. - Blurred vision: temporary visual disturbances. - Weight gain: modest increase in body weight over time. - Orthostatic hypotension: dizziness upon standing.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm that may be life‑threatening. - Seizures: risk of convulsive episodes, particularly in predisposed individuals. - Severe hypotension: marked drop in blood pressure leading to fainting. - Hepatic toxicity: abnormal liver function tests or hepatitis. - Agranulocytosis: dangerously low white‑blood‑cell count. - Suicidal thoughts: emergence or worsening of suicidal ideation.

Before prescribing Imipramine Hydrochloride, clinicians should consider several safety measures. - Assess cardiac history: obtain a baseline ECG and monitor for conduction abnormalities. - Monitor for suicidal ideation: especially during the first few weeks of therapy. - Avoid abrupt discontinuation: taper the dose under medical supervision to prevent withdrawal. - Use caution in elderly patients: increased risk of confusion, falls, and anticholinergic effects. - Avoid concomitant MAO inhibitors: ensure a washout period of at least 14 days. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Imipramine Hydrochloride can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome; maintain a minimum 14‑day washout. - Selective serotonin reuptake inhibitors (SSRIs) or other serotonergic agents: may precipitate serotonin syndrome. - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): increase imipramine plasma levels and toxicity.

Moderate Interactions (Monitor Closely): - Antihypertensive drugs: additive hypotensive effect, monitor blood pressure. - Central nervous system depressants (e.g., benzodiazepines, alcohol): enhanced sedation and respiratory depression. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increased risk of gastrointestinal bleeding.